Literature DB >> 24293470

Pathogenesis of pulmonary arterial hypertension: lessons from cancer.

Christophe Guignabert1, Ly Tu, Morane Le Hiress, Nicolas Ricard, Caroline Sattler, Andrei Seferian, Alice Huertas, Marc Humbert, David Montani.   

Abstract

Although the causal pathomechanisms contributing to remodelling of the pulmonary vascular bed in pulmonary arterial hypertension (PAH) are still unclear, several analogous features with carcinogenesis have led to the emergence of the cancer-like concept. The major similarities concern the altered crosstalk between cells from different tissue types, unexplained proliferation and survival of pulmonary smooth muscle and endothelial cells, the metabolic (glycolytic) shifts, and the association with the immune system. However, major differences between PAH and cancer exist, including the absence of invasion and metastasis, as well as the pathogenic genes involved and the degrees of angiogenesis impairment and genetic instability. It is clear that PAH is not a cancer, but this cancer-like concept has opened a new field of investigation and raises the possibility that antiproliferative and/or oncological drugs may exert therapeutic effects not only in cancer, but also in PAH. Such analogies and differences are discussed here.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24293470     DOI: 10.1183/09059180.00007513

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  66 in total

Review 1.  The crossroads of iron with hypoxia and cellular metabolism. Implications in the pathobiology of pulmonary hypertension.

Authors:  Jeffrey C Robinson; Brian B Graham; Tracey C Rouault; Rubin M Tuder
Journal:  Am J Respir Cell Mol Biol       Date:  2014-12       Impact factor: 6.914

2.  Is pulmonary hypertension a metabolic disease?

Authors:  Jarrod Barnes; Raed A Dweik
Journal:  Am J Respir Crit Care Med       Date:  2014-11-01       Impact factor: 21.405

Review 3.  The role of nuclear factor of activated T cells in pulmonary arterial hypertension.

Authors:  Rui Chen; Jinchuan Yan; Peijing Liu; Zhongqun Wang; Cuiping Wang; Wei Zhong; Liangjie Xu
Journal:  Cell Cycle       Date:  2017-01-19       Impact factor: 4.534

4.  Evolving systems biology approaches to understanding non-coding RNAs in pulmonary hypertension.

Authors:  Lloyd D Harvey; Stephen Y Chan
Journal:  J Physiol       Date:  2018-09-02       Impact factor: 5.182

Review 5.  Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs.

Authors:  Soni Savai Pullamsetti; Rajkumar Savai; Werner Seeger; Elena A Goncharova
Journal:  Am J Respir Crit Care Med       Date:  2017-02-15       Impact factor: 21.405

6.  Translational Advances in the Field of Pulmonary Hypertension. Translating MicroRNA Biology in Pulmonary Hypertension. It Will Take More Than "miR" Words.

Authors:  Hyung J Chun; Sébastien Bonnet; Stephen Y Chan
Journal:  Am J Respir Crit Care Med       Date:  2017-01-15       Impact factor: 21.405

Review 7.  Novel methods in pulmonary hypertension phenotyping in the age of precision medicine (2015 Grover Conference series).

Authors:  Jarrod W Barnes; Adriano R Tonelli; Gustavo A Heresi; Jennie E Newman; Noël E Mellor; David E Grove; Raed A Dweik
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

8.  Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.

Authors:  Christophe Guignabert; Carole Phan; Andrei Seferian; Alice Huertas; Ly Tu; Raphaël Thuillet; Caroline Sattler; Morane Le Hiress; Yuichi Tamura; Etienne-Marie Jutant; Marie-Camille Chaumais; Stéphane Bouchet; Benjamin Manéglier; Mathieu Molimard; Philippe Rousselot; Olivier Sitbon; Gérald Simonneau; David Montani; Marc Humbert
Journal:  J Clin Invest       Date:  2016-08-02       Impact factor: 14.808

9.  Divergent changes of p53 in pulmonary arterial endothelial and smooth muscle cells involved in the development of pulmonary hypertension.

Authors:  Ziyi Wang; Kai Yang; Qiuyu Zheng; Chenting Zhang; Haiyang Tang; Aleksandra Babicheva; Qian Jiang; Meichan Li; Yuqin Chen; Shane G Carr; Kang Wu; Qian Zhang; Angela Balistrieri; Christina Wang; Shanshan Song; Ramon J Ayon; Ankit A Desai; Stephen M Black; Joe G N Garcia; Ayako Makino; Jason X-J Yuan; Wenju Lu; Jian Wang
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-10-25       Impact factor: 5.464

10.  Metabolic Reprogramming Regulates the Proliferative and Inflammatory Phenotype of Adventitial Fibroblasts in Pulmonary Hypertension Through the Transcriptional Corepressor C-Terminal Binding Protein-1.

Authors:  Min Li; Suzette Riddle; Hui Zhang; Angelo D'Alessandro; Amanda Flockton; Natalie J Serkova; Kirk C Hansen; Radu Moldovan; B Alexandre McKeon; Maria Frid; Sushil Kumar; Hong Li; Hongbing Liu; Angela Caánovas; Juan F Medrano; Milton G Thomas; Dijana Iloska; Lydie Plecitá-Hlavatá; Petr Ježek; Soni Pullamsetti; Mehdi A Fini; Karim C El Kasmi; QingHong Zhang; Kurt R Stenmark
Journal:  Circulation       Date:  2016-08-25       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.